LY2181308

LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References

  1. ↑ "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.". Cancer Chemother. Pharmacol. 68 (2): 505–11. Nov 2010. doi:10.1007/s00280-010-1506-7. PMID 21079959.
  2. ↑ http://clinicaltrials.gov/ct2/results?term=LY2181308
  3. ↑ http://www.isispharm.com/Pipeline/Therapeutic-Areas/Cancer.htm#LY2181308
  4. ↑ A phase II Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
  5. ↑ A Phase II Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
  6. ↑ A Phase II Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer


This article is issued from Wikipedia - version of the 7/13/2012. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.